STERIS plc (STE) Stock Competitors & Peer Comparison
See (STE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| STE | $215.67 | +2.41% | 21B | 21.21 | $10.17 | +1.17% |
| ALC | $67.80 | -0.48% | 33.1B | 21.33 | $3.18 | +0.53% |
| PHG | $27.10 | -0.70% | 26.3B | 15.49 | $1.75 | +3.66% |
| BRKRP | $451.04 | +0.35% | 9.3B | 888.96 | $0.51 | +0.33% |
| DRTSW | $2.10 | -8.30% | 1B | -3.25 | -$0.65 | N/A |
| MOBI | $14.63 | +12.45% | 486.4M | -0.78 | -$18.78 | N/A |
| SI | $22.79 | +5.46% | 470.3M | -0.34 | -$65.74 | N/A |
| CV | $7.52 | +7.58% | 375.7M | -3.01 | -$2.50 | N/A |
| MASS | $8.78 | -2.23% | 332M | -14.63 | -$0.60 | N/A |
| APYX | $4.50 | +7.91% | 188.4M | -20.45 | -$0.22 | N/A |
Stock Comparison
STE vs ALC Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, ALC has a market cap of 33.1B. Regarding current trading prices, STE is priced at $215.67, while ALC trades at $67.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas ALC's P/E ratio is 21.33. In terms of profitability, STE's ROE is +0.11%, compared to ALC's ROE of +0.04%. Regarding short-term risk, STE is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for STE.Check ALC's competition here
STE vs PHG Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, PHG has a market cap of 26.3B. Regarding current trading prices, STE is priced at $215.67, while PHG trades at $27.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas PHG's P/E ratio is 15.49. In terms of profitability, STE's ROE is +0.11%, compared to PHG's ROE of +0.09%. Regarding short-term risk, STE is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for STE.Check PHG's competition here
STE vs BRKRP Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, BRKRP has a market cap of 9.3B. Regarding current trading prices, STE is priced at $215.67, while BRKRP trades at $451.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas BRKRP's P/E ratio is 888.96. In terms of profitability, STE's ROE is +0.11%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, STE is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for STE.Check BRKRP's competition here
STE vs DRTSW Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, DRTSW has a market cap of 1B. Regarding current trading prices, STE is priced at $215.67, while DRTSW trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas DRTSW's P/E ratio is -3.25. In terms of profitability, STE's ROE is +0.11%, compared to DRTSW's ROE of -0.73%. Regarding short-term risk, STE is less volatile compared to DRTSW. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check DRTSW's competition here
STE vs MOBI Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, MOBI has a market cap of 486.4M. Regarding current trading prices, STE is priced at $215.67, while MOBI trades at $14.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas MOBI's P/E ratio is -0.78. In terms of profitability, STE's ROE is +0.11%, compared to MOBI's ROE of +0.31%. Regarding short-term risk, STE is less volatile compared to MOBI. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check MOBI's competition here
STE vs SI Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, SI has a market cap of 470.3M. Regarding current trading prices, STE is priced at $215.67, while SI trades at $22.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas SI's P/E ratio is -0.34. In terms of profitability, STE's ROE is +0.11%, compared to SI's ROE of -0.35%. Regarding short-term risk, STE is less volatile compared to SI. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check SI's competition here
STE vs CV Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, CV has a market cap of 375.7M. Regarding current trading prices, STE is priced at $215.67, while CV trades at $7.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas CV's P/E ratio is -3.01. In terms of profitability, STE's ROE is +0.11%, compared to CV's ROE of +1.27%. Regarding short-term risk, STE is less volatile compared to CV. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check CV's competition here
STE vs MASS Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, MASS has a market cap of 332M. Regarding current trading prices, STE is priced at $215.67, while MASS trades at $8.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas MASS's P/E ratio is -14.63. In terms of profitability, STE's ROE is +0.11%, compared to MASS's ROE of -0.26%. Regarding short-term risk, STE is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check MASS's competition here
STE vs APYX Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, APYX has a market cap of 188.4M. Regarding current trading prices, STE is priced at $215.67, while APYX trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas APYX's P/E ratio is -20.45. In terms of profitability, STE's ROE is +0.11%, compared to APYX's ROE of -0.91%. Regarding short-term risk, STE is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check APYX's competition here
STE vs EDAP Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, STE is priced at $215.67, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas EDAP's P/E ratio is -5.80. In terms of profitability, STE's ROE is +0.11%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, STE is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check EDAP's competition here
STE vs HYPR Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, HYPR has a market cap of 123.8M. Regarding current trading prices, STE is priced at $215.67, while HYPR trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas HYPR's P/E ratio is -3.67. In terms of profitability, STE's ROE is +0.11%, compared to HYPR's ROE of -1.01%. Regarding short-term risk, STE is less volatile compared to HYPR. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check HYPR's competition here
STE vs CHRN Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, CHRN has a market cap of 79.2M. Regarding current trading prices, STE is priced at $215.67, while CHRN trades at $22.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas CHRN's P/E ratio is -14.25. In terms of profitability, STE's ROE is +0.11%, compared to CHRN's ROE of N/A. Regarding short-term risk, STE is less volatile compared to CHRN. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check CHRN's competition here
STE vs NYXH Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, NYXH has a market cap of 66.1M. Regarding current trading prices, STE is priced at $215.67, while NYXH trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas NYXH's P/E ratio is -0.67. In terms of profitability, STE's ROE is +0.11%, compared to NYXH's ROE of -1.64%. Regarding short-term risk, STE is less volatile compared to NYXH. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check NYXH's competition here
STE vs MDAI Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, MDAI has a market cap of 54.4M. Regarding current trading prices, STE is priced at $215.67, while MDAI trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas MDAI's P/E ratio is -3.80. In terms of profitability, STE's ROE is +0.11%, compared to MDAI's ROE of +1.79%. Regarding short-term risk, STE is less volatile compared to MDAI. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check MDAI's competition here
STE vs QTEXW Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, QTEXW has a market cap of 10.1M. Regarding current trading prices, STE is priced at $215.67, while QTEXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas QTEXW's P/E ratio is -0.14. In terms of profitability, STE's ROE is +0.11%, compared to QTEXW's ROE of N/A. Regarding short-term risk, STE is less volatile compared to QTEXW. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check QTEXW's competition here
STE vs WOK Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, WOK has a market cap of 5.4M. Regarding current trading prices, STE is priced at $215.67, while WOK trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas WOK's P/E ratio is N/A. In terms of profitability, STE's ROE is +0.11%, compared to WOK's ROE of -0.07%. Regarding short-term risk, STE is less volatile compared to WOK. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check WOK's competition here
STE vs BIAFW Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, BIAFW has a market cap of 3.8M. Regarding current trading prices, STE is priced at $215.67, while BIAFW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas BIAFW's P/E ratio is N/A. In terms of profitability, STE's ROE is +0.11%, compared to BIAFW's ROE of -3.59%. Regarding short-term risk, STE is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for STE.Check BIAFW's competition here
STE vs ITOC Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, ITOC has a market cap of 2.9M. Regarding current trading prices, STE is priced at $215.67, while ITOC trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas ITOC's P/E ratio is -0.99. In terms of profitability, STE's ROE is +0.11%, compared to ITOC's ROE of -0.44%. Regarding short-term risk, STE is less volatile compared to ITOC. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check ITOC's competition here
STE vs FEED Comparison June 2026
STE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, STE stands at 21B. In comparison, FEED has a market cap of 633.9K. Regarding current trading prices, STE is priced at $215.67, while FEED trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
STE currently has a P/E ratio of 21.21, whereas FEED's P/E ratio is -0.01. In terms of profitability, STE's ROE is +0.11%, compared to FEED's ROE of -0.44%. Regarding short-term risk, STE is less volatile compared to FEED. This indicates potentially lower risk in terms of short-term price fluctuations for STE.Check FEED's competition here